JANUX THERAPEUTICS INC (JANX)

US47103J1051 - Common Stock

50.82  -6.99 (-12.09%)

After market: 50.84 +0.02 (+0.04%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
3.64M8.61M
136.54%
8.083M
-6.12%
11.338M
40.27%
3.42M
-69.84%
8.157M
138.51%
8.395M
2.92%
89.49M
965.99%
393.82M
340.07%
881.81M
123.91%
1.266B
43.57%
EBITDA
YoY % growth
-32.82M
-579.50%
-66.25M
-101.86%
-71.024M
-7.21%
-104.611M
-47.29%
-138.047M
-31.96%
-149.665M
-8.42%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
-32.93M
-580.37%
-67.09M
-103.74%
-72.979M
-8.78%
-98.368M
-34.79%
-132.723M
-34.92%
-168.924M
-27.28%
-206.749M
-22.39%
-190.763M
7.73%
-11.838M
93.79%
336.15M
2,939.64%
601.36M
78.90%
Operating Margin
-904.67%-779.21%-902.87%-867.59%-3,880.78%-2,070.91%-2,462.76%-213.17%-3.01%38.12%47.50%
EPS
YoY % growth
N/A-1.52
-19.43%
-1.34
11.84%
-1.37
-2.28%
-2.02
-47.36%
-2.61
-29.20%
-3.67
-40.67%
-3.18
13.30%
-0.92
71.21%
3.55
487.77%
5.80
63.14%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-0.44
-75.44%
-0.42
-41.34%
-0.44
-304.02%
-0.47
7.43%
-0.48
-9.63%
-0.39
8.59%
-0.40
10.49%
-0.44
7.10%
-0.55
-14.55%
Revenue
Q2Q % growth
274.268K
-88.86%
291.424K
-76.72%
291.424K
-96.72%
364.283K
-17.02%
364.283K
32.82%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
-34.109M
-140.51%
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-28.422M
-76.13%
-26.979M
-33.82%
-28.28M
-104.60%
-30.6M
14.63%
-32.972M
-16.01%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.51
-104.00%
-0.33-0.18-52.65%
Q2 2024
Q2Q % growth
-0.11
73.81%
-0.320.2165.71%
Q1 2024
Q2Q % growth
-0.30
28.57%
-0.340.0411.21%
Q4 2023
Q2Q % growth
-0.25
35.90%
-0.400.1537.59%
Q3 2023
Q2Q % growth
-0.25
37.50%
-0.480.2347.85%
Q2 2023
Q2Q % growth
-0.42
-2.44%
-0.530.1120.43%
Q1 2023
Q2Q % growth
-0.42
-31.25%
-0.500.0816.27%
Q4 2022
Q2Q % growth
-0.39
-18.18%
-0.500.1121.41%
Q3 2022
Q2Q % growth
-0.40
-53.85%
-0.500.1019.47%
Q2 2022
Q2Q % growth
-0.41
33.87%
-0.38-0.03-8.25%
Q1 2022
Q2Q % growth
-0.32 -0.380.0614.75%
Q4 2021
Q2Q % growth
-0.33 -0.31-0.02-5.27%
Q3 2021
Q2Q % growth
-0.26 -0.18-0.08-44.28%
Q2 2021
Q2Q % growth
-0.62 -0.13-0.49-367.57%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
439K
-82.56%
1.674M-1.235M-73.78%
Q2 2024
Q2Q % growth
8.897M
741.72%
782.789K8.114M1,036.58%
Q1 2024
Q2Q % growth
1.252M
-38.87%
778.648K473.352K60.79%
Q4 2023
Q2Q % growth
2.461M
-13.65%
754.035K1.707M226.38%
Q3 2023
Q2Q % growth
2.517M
39.06%
862.41K1.655M191.86%
Q2 2023
Q2Q % growth
1.057M
-55.40%
892.5K164.5K18.43%
Q1 2023
Q2Q % growth
2.048M
28.81%
685.695K1.362M198.68%
Q4 2022
Q2Q % growth
2.85M
75.93%
808.095K2.042M252.68%
Q3 2022
Q2Q % growth
1.81M
56.03%
758.197K1.052M138.72%
Q2 2022
Q2Q % growth
2.37M
393.75%
863.603K1.506M174.43%
Q1 2022
Q2Q % growth
1.59M
318.42%
834.697K755.303K90.49%
Q4 2021
Q2Q % growth
1.62M 441.997K1.178M266.52%
Q3 2021
Q2Q % growth
1.16M 135.997K1.024M752.96%
Q2 2021
Q2Q % growth
480K 204K276K135.29%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -18.99% -0.11% -18.72%
Revenue0% -66.85% 1.91% -5.45%